-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
CinCor Pharma, Inc. (NASDAQ:CINC) Receives Consensus Rating of "Moderate Buy" From Brokerages
CinCor Pharma, Inc. (NASDAQ:CINC) Receives Consensus Rating of "Moderate Buy" From Brokerages
Shares of CinCor Pharma, Inc. (NASDAQ:CINC – Get Rating) have received an average rating of "Moderate Buy" from the eight analysts that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $45.83.
A number of equities analysts recently weighed in on CINC shares. Oppenheimer lowered shares of CinCor Pharma from an "outperform" rating to a "market perform" rating in a research report on Monday, November 28th. Piper Sandler reduced their target price on shares of CinCor Pharma from $73.00 to $53.00 in a research note on Monday, November 28th. The Goldman Sachs Group began coverage on shares of CinCor Pharma in a research note on Friday, October 28th. They set a "buy" rating and a $67.00 target price on the stock. Morgan Stanley lifted their target price on shares of CinCor Pharma from $22.00 to $30.00 and gave the stock an "equal weight" rating in a research note on Tuesday, January 10th. Finally, Barclays downgraded shares of CinCor Pharma from an "overweight" rating to an "equal weight" rating and lifted their target price for the stock from $22.00 to $31.00 in a research note on Thursday, January 12th.
Get CinCor Pharma alerts:CinCor Pharma Stock Performance
CINC opened at $28.80 on Friday. CinCor Pharma has a fifty-two week low of $10.53 and a fifty-two week high of $43.15. The company has a fifty day moving average of $18.38 and a two-hundred day moving average of $26.05. The stock has a market capitalization of $1.26 billion and a price-to-earnings ratio of -1.67.
CinCor Pharma (NASDAQ:CINC – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.08. On average, equities research analysts forecast that CinCor Pharma will post -2.14 earnings per share for the current year.Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. American International Group Inc. boosted its holdings in shares of CinCor Pharma by 8.9% in the 2nd quarter. American International Group Inc. now owns 6,272 shares of the company's stock valued at $118,000 after buying an additional 511 shares in the last quarter. Amalgamated Bank boosted its stake in CinCor Pharma by 27.0% during the 3rd quarter. Amalgamated Bank now owns 2,670 shares of the company's stock worth $88,000 after purchasing an additional 567 shares during the period. Bartlett & Co. LLC acquired a new stake in CinCor Pharma during the 3rd quarter worth $26,000. Walleye Capital LLC boosted its stake in CinCor Pharma by 3.8% during the 2nd quarter. Walleye Capital LLC now owns 29,323 shares of the company's stock worth $552,000 after purchasing an additional 1,073 shares during the period. Finally, Credit Suisse AG boosted its stake in CinCor Pharma by 18.1% during the 3rd quarter. Credit Suisse AG now owns 12,043 shares of the company's stock worth $395,000 after purchasing an additional 1,850 shares during the period. Institutional investors and hedge funds own 99.15% of the company's stock.
CinCor Pharma Company Profile
(Get Rating)
CinCor Pharma, Inc, a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases.
Further Reading
- Get a free copy of the StockNews.com research report on CinCor Pharma (CINC)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for CinCor Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CinCor Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
據市場評級公司報道,新科醫藥股份有限公司(納斯達克代碼:CINC-GET Rating)的股票從目前跟蹤該股票的八位分析師那裡獲得了平均評級為“中等買入”。三位股票研究分析師對該股的評級為持有建議,四位分析師給出了買入建議。在過去一年追蹤該股的券商中,1年目標價的平均水準為45.83美元。
許多股票分析師最近紛紛買入中集集團的股票。在11月28日週一的一份研究報告中,奧本海默將CinCor Pharma的股票評級從“跑贏大盤”下調至“市場表現”。派珀·桑德勒在11月28日週一的一份研究報告中將CinCor Pharma的股票目標價從73.00美元下調至53.00美元。10月28日,星期五,高盛在一份研究報告中開始對CinCor Pharma的股票進行報道。他們為該股設定了“買入”評級和67.00美元的目標價。1月10日,週二,摩根士丹利在一份研究報告中將CinCor Pharma的目標價從22.00美元上調至30.00美元,並給予該股“同等權重”的評級。最後,巴克萊在1月12日週四的一份研究報告中,將CinCor Pharma的股票評級從增持下調至同等權重,並將其目標價從22.00美元上調至31.00美元。
到達CinCor Pharma警報:CinCor Pharma股票表現
CINC上週五開盤報28.80美元。CinCor Pharma的股價為52周低點10.53美元,52周高點為43.15美元。該公司的50日移動均線切入位在18.38美元,200日移動均線切入位在26.05美元。該股市值為12.6億美元,本益比為-1.67倍。
新科醫藥(納斯達克代碼:CINC-GET Rating)最近一次發佈季度收益數據是在11月3日星期四。該公司公佈了該季度每股收益(0.51美元),比分析師普遍預期的(0.59美元)高出0.08美元。股票研究分析師平均預測,CinCor Pharma本年度每股收益將達到2.14美元。機構資金流入和流出
幾家大型投資者最近調整了對該股的持股比例。美國國際集團(American International Group Inc.)在第二季度增持了CinCor Pharma的股票8.9%。美國國際集團目前持有該公司6,272股股票,價值11.8萬美元,該公司在上個季度又購買了511股。合併銀行在第三季度將其在CinCor Pharma的持股增加了27.0%。合併銀行在此期間額外購買了567股,現在擁有2670股該公司股票,價值8.8萬美元。Bartlett&Co.LLC在第三季度收購了CinCor Pharma價值2.6萬美元的新股份。Walleye Capital LLC在第二季度將其在CinCor Pharma的持股增加了3.8%。Walleye Capital LLC現在擁有29,323股該公司的股票,價值552,000美元,在此期間又購買了1,073股。最後,瑞士信貸(Credit Suisse AG)在第三季度增持了CinCor Pharma 18.1%的股份。瑞士信貸(Credit Suisse AG)在此期間又購買了1,850股,目前持有該公司12,043股股票,價值395,000美元。機構投資者和對沖基金持有該公司99.15%的股票。
CinCor製藥公司簡介
(獲取評級)
CinCor Pharma,Inc.是一家臨床階段的生物製藥公司,致力於開發治療心腎疾病的藥物。它參與了CIN-107的開發,這是治療高血壓、原發性醛固酮增多症和其他心腎疾病的第二階段臨床試驗,以及治療慢性腎臟疾病的第一階段臨床試驗。
進一步閱讀
- 免費獲取StockNews.com關於CinCor Pharma(CINC)的研究報告
- 市場回顧周-1/23-1/27
- 為什麼Lucid在一天內飆升了近100%
- 利用這些鐵路股票實現增長和收入
- ASML預計今年晶片需求回升,提振銷售觀點
- KLA公司:在動盪不安的半市場中站穩腳跟
接受CinCor Pharma Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對CinCor Pharma和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧